Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gp100:209-217 (NYU Langone Health)
- Development stage
- Unknown
- Lead developer
- NYU Langone Health
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
**gp100:209-217** is an investigational synthetic tumor-associated antigen peptide vaccine component derived from glycoprotein 100. In the NYU Langone Health Phase I pediatric central nervous system tumor study, it was administered by subcutaneous injection as one of four tumor-associated peptide antigens in a Montanide ISA-51VG-adjuvanted vaccine regimen. The intended mechanism is induction of antigen-specific cellular immune responses against tumor cells expressing gp100. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00935545))
- Other names
- gp100 209-217gp-100 209-217gp 100 209-217gp100:209-217
02
Targets
PMEL (Melanocyte Protein PMEL)TYRP2 (Tyrosinase-related Protein 2)ERBB2 (Erb-b2 receptor tyrosine kinase 2)EPHA2 (Ephrin type-A receptor 2)
Beyond the preview
Go deeper on gp100:209-217 (NYU Langone Health).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gp100:209-217 (NYU Langone Health).